THE COVID-19 RACE how mouse models will help researchers cross the finish line By Dr Megan MacBride The emergence of SARS-CoV-2 virus and the disease it causes, COVID-19, have fuelled significant shifts in preclinical research across the globe. Amid the worldwide health emergency created by high infection rates, rapid transmission… Read More
By Dr Ross Macdonald Cell-based therapies are being widely recognised for their potential to treat a variety of medical conditions, but they face major obstacles toward commercialisation. Traditionally, they have been difficult and expensive to make in large quantities. Biopharmaceutical companies must develop manufacturing solutions that will enable them to… Read More
The COVID-19 antiviral race: we're all in this together By Uduak Grace Thomas In response to the COVID-19 pandemic, international scientists from academia and industry have pooled their expertise and resources to identify candidate compounds that inhibit the activity of the SARS-CoV-2 main protease, in order to develop a clinically… Read More
The CELL CULTURE innovations increasing drug discovery success By Helen Stewart-Miller and Abby George Volume 21 Issue 3 - Summer 2020 'Fail early, fail fast' has been a mantra in the pharmaceutical industry for several years and directly impacts the overall strategy of many drug discovery and development programmes. Yet,… Read More
Stem Cell Differentiation By Dr Lilian Hook Stem cells are extraordinary cells, capable of both self-renewal and differentiation to mature somatic cells in vivo and in vitro (1,2). They have many features and advantages which could revolutionise drug development and healthcare applications. Stem cells offer a limitless, consistent supply of… Read More
Advanced Therapeutic Antibody Discovery with Multiplexed Screening Sponsored by Sartorius Antibody-based therapeutics are the fastest growing and most successful therapeutic modality for treating diseases such as cancer, cardiovascular disease, autoimmune disorders and infectious disease. It is predicted that by the year 2020 there will be 70 therapeutic antibodies on the… Read More
Leading in vivo pharmacology and consultancy services firm RenaSci, part of the Sygnature Group, have bolstered their Kidney Disease and Fibrosis capabilities with the appointment of Dr Wioletta Pijacka. Wioletta is an in vivo translational biologist with over 12 years of experience in renal and cardio-vascular… Read More
According to the Humane Society International/UK (HSI/UK), Home Office statistics reveal that the number of animals in British laboratories has stayed broadly the same almost a decade after the government pledged to reduce animal use. It says that UK laboratories completed a total of 3.4 million procedures in… Read More
Computational modeling yields a protein fragment that could bind to coronavirus spike proteins and destroy them by Anne Trafton, MIT News Office The research described in this article has been published on a preprint server but has not yet been peer-reviewed by scientific or medical experts. Using computational models… Read More
24 June 2020 A survey has revealed that 93.4% of respondents think more needs to be done to replace and reduce the use of animals in testing and research. The study by independent scientific research charity FRAME (Fund for the Replacement of Animals in Medical Experiments), also found that over half think… Read More
06 May, 2020 Spain based private biotechnology company Algenex announced that it is advancing the application of its CrisBio-based vaccine production technology in human health. Building on its expertise in the production of proteins for veterinary vaccines, Algenex said it has started to produce biotechnology products for the… Read More
ADCs and solid tumours - The payload revolution that drives therapeutic opportunities in unmet need By Dr Jenny Thirlway Volume 21 Issue 2 - Spring 2020 The fight against cancer is ongoing. Despite progress in many indications, mortality rates for some of the most difficult to treat solid tumour types… Read More
Reprogramming the stem cell for a new generation of cures By Dr Alex Davenport, Dr Tonya Frolov and Dr Mark Kotter Volume 21 Issue 2 - Spring 2020 The development of new and effective treatments with the potential to cure, or at the very least ease patient suffering, has been… Read More
By Dr Steve Arlington and John Wise As part of its mission to help members anticipate and prepare for changes in the pharmaceutical industry, The Pistoia Alliance has developed a research paper which sets out to consider what the life science, biopharma R&D and healthcare ecosystem might look like in… Read More
How Artificial Intelligence is Transforming Drug Design By Dr Mark Roberts and Dr Sam Genway AI could create a streamlined, automated approach to drug discovery, trawling vast datasets to identify targets, find candidate molecules and predict synthesis routes. Getting there will require significant vision, but we are already seeing exciting… Read More
By Dr Alexander C. Maue It has become quite evident that the microbiome has the potential to impact drug discovery in vital ways. In addition to impacting study reproducibility and variability, the microbiome may influence drug efficacy or serve as a therapeutic agent. To capitalise on the microbiome’s potential to… Read More